Skip to content
10-Q

Quarterly Report

TARSUS PHARMACEUTICALS, INC. TARS

0001819790-25-000121

← back to feed
Filed
Nov 4, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 29, 2025 42.45M sh
Shares Diluted Q3 2025 · Sep 30, 2025 42.61M sh
Shares Diluted Q3 2025 · Sep 30, 2025 41.46M sh
Shares Diluted Q3 2025 · Sep 30, 2024 38.38M sh
Shares Diluted Q3 2025 · Sep 30, 2024 37.29M sh
Capex Q3 2025 · Sep 30, 2025 $3.5M
Capex Q3 2025 · Sep 30, 2024 $1.5M
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$31.78M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$60.85M
Long Term Debt Q3 2025 · Sep 30, 2025 $72.28M
Long Term Debt Q3 2025 · Dec 31, 2024 $71.85M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $112.72M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $94.82M
Stockholders Equity Q3 2025 · Sep 30, 2025 $335.08M
Stockholders Equity Q3 2025 · Jun 30, 2025 $332.61M
Stockholders Equity Q3 2025 · Mar 31, 2025 $342.46M
Stockholders Equity Q3 2025 · Dec 31, 2024 $224.53M
Stockholders Equity Q3 2025 · Sep 30, 2024 $237.48M
Stockholders Equity Q3 2025 · Jun 30, 2024 $252.25M
Stockholders Equity Q3 2025 · Mar 31, 2024 $275.21M
Stockholders Equity Q3 2025 · Dec 31, 2023 $196.99M
Current Liabilities Q3 2025 · Sep 30, 2025 $117.05M
Current Liabilities Q3 2025 · Dec 31, 2024 $80.61M
Total Liabilities Q3 2025 · Sep 30, 2025 $199.48M
Total Liabilities Q3 2025 · Dec 31, 2024 $152.46M
Current Assets Q3 2025 · Sep 30, 2025 $501.7M
Current Assets Q3 2025 · Dec 31, 2024 $356.71M
Total Assets Q3 2025 · Sep 30, 2025 $534.56M
Total Assets Q3 2025 · Dec 31, 2024 $376.99M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.30
Eps Diluted Q3 2025 · Sep 30, 2025 −$1.40
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.61
Eps Diluted Q3 2025 · Sep 30, 2024 −$2.48
Eps Basic Q3 2025 · Sep 30, 2025 −$0.30
Eps Basic Q3 2025 · Sep 30, 2025 −$1.40
Eps Basic Q3 2025 · Sep 30, 2024 −$0.61
Eps Basic Q3 2025 · Sep 30, 2024 −$2.48
Sga Expense Q3 2025 · Sep 30, 2025 $108.63M
Sga Expense Q3 2025 · Sep 30, 2025 $296.64M
Sga Expense Q3 2025 · Sep 30, 2024 $57.91M
Sga Expense Q3 2025 · Sep 30, 2024 $168.28M
Rd Expense Q3 2025 · Sep 30, 2025 $16.28M
Rd Expense Q3 2025 · Sep 30, 2025 $46.29M
Rd Expense Q3 2025 · Sep 30, 2024 $12.13M
Rd Expense Q3 2025 · Sep 30, 2024 $36.51M
Net Income Q3 2025 · Sep 30, 2025 −$12.59M
Net Income Q3 2025 · Sep 30, 2025 −$58.05M
Net Income Q3 2025 · Jun 30, 2025 −$20.34M
Net Income Q3 2025 · Mar 31, 2025 −$25.12M
Net Income Q3 2025 · Sep 30, 2024 −$23.42M
Net Income Q3 2025 · Sep 30, 2024 −$92.44M
Net Income Q3 2025 · Jun 30, 2024 −$33.29M
Net Income Q3 2025 · Mar 31, 2024 −$35.73M
Operating Income Q3 2025 · Sep 30, 2025 −$14.53M
Operating Income Q3 2025 · Sep 30, 2025 −$62.99M
Operating Income Q3 2025 · Sep 30, 2024 −$25.16M
Operating Income Q3 2025 · Sep 30, 2024 −$96.15M
Revenue Q3 2025 · Sep 30, 2025 $118.7M
Revenue Q3 2025 · Sep 30, 2025 $299.69M
Revenue Q3 2025 · Sep 30, 2024 $48.12M
Revenue Q3 2025 · Sep 30, 2024 $116.55M